101 Therapeutics
Developing Cures for Multiple Infectious Diseases
Startup Seed Health Tech & Life Sciences Est. 2020
Total Raised
Undisclosed
Seed
Last Round
Undisclosed
1 rounds
Investors
1
1 public
Team
2
1-10 employees
Confidence
89/100
News
1
articles
About
101 Therapeutics has developed the first-ever targeted glucocorticoid with all of the potency of steroids and none of the systemic toxicities. By targeting the host immune system rather than the pathogen itself, the company can effectively treat a multitude of infectious diseases, whether viral, parasitic, or bacterial.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
biotechnologypharmaceuticalsinfectious-diseasedrug-developmentdrug-discovery
Funding & Events
Apr 2023
Undisclosed Round Undisclosed
Awz Ventures (Lead)
News (1)
May 6, 2023 · www.deccanchronicle.com
growth-positive
CSIR-IICT signs MoU with 101 Therapeutics Israel for new drug for Covid-19
PartnersCustomers
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
3
Founded
2020
Registrar
516273422
Locations
Tel Aviv-Yafo, Israel
Links
Admin
Last Update
Jun 7, 2024
Verified by
Yanina Wainscheinker
Missing
video or image, markets, not claimed
Team (2)
Alec Goldberg
Co-founder & CEO
Founder
James Goldberg
Co-founder
Founder
Internal
Created by
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Created
2023-05-10T00:00:00.000Z